Survivin as a diagnostic and therapeutic marker for thyroid cancer

Pathol Res Pract. 2019 Apr;215(4):619-625. doi: 10.1016/j.prp.2019.01.025. Epub 2019 Jan 18.

Abstract

Thyroid cancer (TC) is known as the most prevalent form of endocrine malignancy. With regard to high heterogeneity of the nodules, problem of discriminating between benign and malignant ones in terms of pathological characteristics, as well as lack of appropriate molecular markers; significant efforts are being made to identify molecular markers that able to detect tumorous lesions. Survivin, the newest member of the family of proteins inhibiting cell apoptosis, has been recently considered as a novel molecule marker for cancer. Studies on TC have also demonstrated distinctive expression of survivin and its splice variants in cancer cells compared to normal ones. Therefore, detection of survivin expression and its new splice variants can be utilized to identify tumor nodules and distinguish them from non-cancerous ones, along with other routine laboratory methods.

Keywords: Biomarker; Survivin; Thyroid cancer.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / metabolism*
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Prognosis
  • Survivin / metabolism*
  • Thyroid Neoplasms / diagnosis*
  • Thyroid Neoplasms / metabolism
  • Thyroid Neoplasms / pathology
  • Thyroid Neoplasms / therapy

Substances

  • BIRC5 protein, human
  • Biomarkers, Tumor
  • Survivin